Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immunicum AB Announces Promising Data for Cancer Vaccine INTUVAX in Treatment of Kidney Cancer


Monday, 20 May 2013 06:26am EDT 

Immunicum AB announced that the Company is to present promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX in the treatment of metastatic renal cell carcinoma at Avanza Bank's Stock Exchange Day. Two patients with poor prognosis have thus far shown an average survival of about 11 months, which can be compared to the expected median survival of five months. The clinical trial will include a total of 12 patients with metastatic renal cell carcinoma of which nine have been treated to date. The treatment consists of two intratumoral injections/vaccinations with INTUVAX every two weeks, after which the cancerous kidney is surgically removed. All treated patients are still alive and injection of INTUVAX has not had a negative impact on patients' general condition and no serious side effects have been reported. No patients have so far been considered in need of additional treatment with established kidney cancer drugs.